Daflon | For Heavy, Painful legs and Varicose Veins | Recommended, non prescription brand for treating chronic venous insufficiency symptoms

More about Daflon | CVD – Chronic Veinous Disease

**Recommended, non prescription brand for treating chronic venous insufficiency symptoms^1^**

Diosmin + Hesperidin (Daflon® 1000) For Heavy, Painful legs and Varicose Veins

Venoactive treatments, like Diosmin + Hesperidin (Daflon® 1000), are designed to help improve our leg vein health by strengthening the tone of our veins, which continue to weaken as chronic venous insufficiency progresses.

Diosmin + Hesperidin (Daflon® 1000) has a dual mechanism of action; its venous anti-inflammatory action venoprotective reduces pain and swelling; it also protects the capillaries or tiny blood vessels to improve microcirculation and venous tone for better vein health and relief of symptoms such as leg pain, and swelling.^2^

How does Diosmin + Hesperidin (Daflon® 1000) work?

Diosmin + Hesperidin (Daflon® 1000) is a clinically proven, effective and convenient oral treatment derived from immature oranges and specially formulated for maximum absorption.^2^

This improved absorption means Diosmin + Hesperidin (Daflon® 1000) can get to the root of the problem and effectively treat veins from the inside, improving the tone of veins, potentially protecting against disease progression and providing relief from heavy, painful leg symptoms.^2^

Tackle leg pain from the inside

Specially formulated from small, immature oranges using a micronisation process, Diosmin + Hesperidin (Daflon® 1000) is absorbed twice as well as non micronised alternatives for effective relief from painful symptoms.^3^

Improved Absorption

Recommended, non prescription brand for treating chronic venous insufficiency symptoms.^1^

Clinical Studies have shown that Diosmin + Hesperidin (Daflon® 1000) can reduce leg pain and the sensations of heaviness and swelling by up to 50% after only one month of use. These figures were even higher after two months of treatment.

To benefit from your Diosmin + Hesperidin (Daflon® 1000) treatment, you should take your medication as recommended. Be sure to monitor your condition closely and speak with a health care professional if you have any concerns.

Demonstrated effect of Diosmin + Hesperidin (Daflon® 1000) **Over 8 weeks**

Leg pain 

Sensation of heaviness

Sensation of swelling

Relieves Symptoms

Diosmin + Hesperidin (Daflon® 1000) is a venoactive drug treatment which, thanks to its venous anti-inflammatory and venoprotective actions, can potentially prevent the development and progression of chronic venous insufficiency.^2^
This progressive condition requires treatment from the earliest stages of disease. Lifestyle changes, compression stockings and using a venoactive drug treatment that tackles the root cause of the problem can help alleviate painful symptoms. By treating early with Diosmin + Hesperidin (Daflon® 1000) you can help relieve symptoms and prevent them getting worse.^5^

Why you should treat early

Diosmin + Hesperidin (Daflon® 1000) can be used from the earliest signs and prevents the development and progression of the disease. ^2^

Convenient Oral Dosing

The active ingredient in Diosmin + Hesperidin (Daflon® 1000) is a micronized purified flavonoid fraction (MPFF)^6^ containing 90% diosmin and 10% other flavonoids expressed as hesperidin.

Diosmin + Hesperidin (Daflon® 1000)’s flavonoids are extracted from immature oranges that are rich in these naturally occurring plant chemicals. The compounds undergo a process of purification and refinement where the particles are made to collide with each other at high speeds (micronization), reducing them to tiny particles, less than 2 μm in size (micronized). These smaller particles are absorbed twice as easily by the body and are a key ingredient of Diosmin + Hesperidin (Daflon® 1000)’s success as a treatment for improving vein health and tone in **Chronic Venous Insufficiency and Hemorrhoids.** ^6^

Diosmin + Hesperidin (Daflon® 1000). Naturally sourced, scientifically prepared.

Safety Information:

<ol>
<li>IQVIA Daflon sales data MAT Q2 2021</li>
<li>Adapted from Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181-254.1</li>
<li>Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91:32-40.</li>
<li>Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9:67-70.</li>
<li>Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008;35(1):102-110.</li>
<li>Summary of Product Characteristics Daflon</li>
</ol>